Fusafungine

Fusafungine

Clinical data
Synonyms	Fusafungin
AHFS/Drugs.com	International Drug Names
ATC code	R02AB03 (WHO)
Identifiers
CAS Number	1393-87-9 Y
DrugBank	DB08965 N
UNII	65DD690W0C
KEGG	D08002 N
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C29H51N2O8
Molar mass	555.72 g/mol
NY (what is this?)  (verify)

WikiDoc Resources for Fusafungine
Articles
Most recent articles on Fusafungine Most cited articles on Fusafungine Review articles on Fusafungine Articles on Fusafungine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Fusafungine Images of Fusafungine Photos of Fusafungine Podcasts & MP3s on Fusafungine Videos on Fusafungine
Evidence Based Medicine
Cochrane Collaboration on Fusafungine Bandolier on Fusafungine TRIP on Fusafungine
Clinical Trials
Ongoing Trials on Fusafungine at Clinical Trials.gov Trial results on Fusafungine Clinical Trials on Fusafungine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Fusafungine NICE Guidance on Fusafungine NHS PRODIGY Guidance FDA on Fusafungine CDC on Fusafungine
Books
Books on Fusafungine
News
Fusafungine in the news Be alerted to news on Fusafungine News trends on Fusafungine
Commentary
Blogs on Fusafungine
Definitions
Definitions of Fusafungine
Patient Resources / Community
Patient resources on Fusafungine Discussion groups on Fusafungine Patient Handouts on Fusafungine Directions to Hospitals Treating Fusafungine Risk calculators and risk factors for Fusafungine
Healthcare Provider Resources
Symptoms of Fusafungine Causes & Risk Factors for Fusafungine Diagnostic studies for Fusafungine Treatment of Fusafungine
Continuing Medical Education (CME)
CME Programs on Fusafungine
International
Fusafungine en Espanol Fusafungine en Francais
Business
Fusafungine in the Marketplace Patents on Fusafungine
Experimental / Informatics
List of terms related to Fusafungine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Fusafungine (INN), also known as fusafungin, is an active agent used in antibiotics for treatment of nasal and throat infection. It also possesses anti-inflammatory properties. Fusafungine is a mixture of enniatin cyclohexadepsipeptides made up of alternating D-α-hydroxyvaleric acid and L-N-methylamino acid residues, produced by the ascomycete Fusarium lateritium, and marketed by Servier under the trade names Locabiotal, Bioparox, and Locabiosol.

According to a pooled analysis study done in the UK for the efficacy of fusafungine in rhinopharingitis, it was found that the proportion of patients who showed an improvement in symptoms from Day 0 to Day 4 of infection was 61.5% with fusafungine vs. 46.8% when compared to a placebo.